论文部分内容阅读
CV205-502是一种新的多巴胺激动剂,本研究用此药治疗7例对溴隐亭抵抗的泌乳素瘤患者。病人和方法7例泌乳素瘤患者,女6例,男1例,年龄22～74岁。所有患者血泌乳素(PRL)水平均升高,对促甲状腺素释放激素(TRH)无反应,无其它原因引起的高PRL血症,其它垂体激素水平正常。6例为大腺瘤,1例CT检查正常。全部病例均先用溴隐亭治疗,剂量很快增至15mg/d,持续治疗至少3个月。治疗后PRL水平均未降到正常。停用溴隐亭4周后改用CV205-502治疗,第1周750μg/d,1个月时逐渐增至100μg/d,每晚顿服。每月测PRL—
CV205-502, a new dopamine agonist, was used in this study to treat 7 patients with bromocriptine-resistant prolactinomas. Patients and methods 7 cases of prolactinoma patients, 6 females, 1 males, aged 22 to 74 years. All patients with elevated serum prolactin (PRL) levels, no response to thyrotropin-releasing hormone (TRH), no other cause of high PRL hyperlipidemia, and other pituitary hormone levels were normal. 6 cases of large adenoma, 1 case of CT examination was normal. All cases were treated with bromocriptine first dose quickly increased to 15mg / d, continuous treatment for at least 3 months. PRL levels after treatment did not fall to normal. Turn off bromocriptine 4 weeks after the switch to CV205-502 treatment, the first week of 750μg / d, gradually increased to 100μg / d at 1 month, Dayton clothing. Measured monthly PRL-